research FDA approves Pfizer's JAK inhibitor for adolescents with alopecia areata hair loss
The FDA approved a new Pfizer drug for hair loss in teens.
Search
for
Sort by
Research
30 / 1000+ resultsresearch Case of de novo nail psoriasis triggered by the second dose of Pfizer-BioNTech BNT162b2 COVID-19 messenger RNA vaccine
The Pfizer COVID-19 vaccine may rarely trigger nail psoriasis.
research A case of extensive alopecia areata following Pfizer‐BioNTech BNT162b2 mRNA COVID‐19 vaccine with favorable outcome
A woman's hair mostly regrew after hair loss from the COVID-19 vaccine with treatment.
research Alopecia areata following COVID-19 vaccine: a systematic review
Alopecia areata after COVID-19 vaccination is rare but important to recognize for timely treatment.
research Alopecia Areata after COVID-19 Vaccines
Some people with a history of autoimmune hair loss experienced worsening symptoms after COVID-19 vaccination.
research Letter in Reply: Alopecia areata after SARS-CoV-2 vaccination
A woman developed alopecia after her second Pfizer vaccine but regrew her hair with treatment and had no issues after a booster shot.
research A Case Series and Literature Review of Telogen Effluvium and Alopecia Universalis after the Administration of a Heterologous COVID-19 Vaccine Scheme
Some people experienced hair loss after COVID-19 vaccination, but it's very rare and vaccines' benefits are greater than this risk.
research Medication-induced hair loss: An update
COVID-19 vaccines have been linked to an increase in hair loss conditions.
research BH07 The socioeconomic burden of alopecia areata
Alopecia areata causes significant financial strain, especially for women and those with severe symptoms.
research Peripilar Sign in Androgenetic Alopecia: Does It Really Indicate Peripilar Infiltrate?
The Peripilar sign does not indicate perifollicular infiltrate in hair loss from Androgenetic Alopecia.
research 564 Subpopulations of dermal fibroblasts produce distinct extracellular matrices
Different types of skin cells create unique support structures that can affect skin cell growth and could help in skin repair.
research 1378 A multi-omics approach to identifying factors involved in hair follicle growth and development
The research found that certain factors in hair follicle cells control hair growth and development, and these could be used to create new treatments for hair loss.
research Side Effects of COVID-19 Vaccination Among Medical Students in Bangladesh: A Cross-Sectional Study
COVID-19 vaccines caused mostly mild side effects in Bangladeshi medical students, with fewer issues after more doses.
research Updated Integrated Safety Analysis of Ritlecitinib up to ~5 Years in Adolescents With Alopecia Areata From the ALLEGRO Clinical Trials
Ritlecitinib is generally safe for adolescents with alopecia areata over 5 years.
research Updated Integrated Efficacy Analysis of Ritlecitinib Up to 3 Years in Adolescents With Alopecia Areata From the ALLEGRO Clinical Trials
Ritlecitinib is effective long-term for treating alopecia areata in teens.
research BH23 Mind the gap! Navigating barriers to care access for patients with alopecia areata in the UK: a qualitative interview study
Patients with alopecia areata in the UK face barriers to care, needing better-defined pathways and more education for general practitioners.
research Guest Editor's Note
The supplement aims to improve care for children with alopecia areata.
research How coronavirus disease 2019 vaccination affect the level of vitamin D in serum and hair?
COVID-19 vaccination may lower vitamin D levels and cause hair loss.
research Efficacy of Ritlecitinib in Patients with Alopecia Areata by Extent of Hair Loss: Results from the Phase 2b/3 and Phase 3 ALLEGRO Clinical Trials
Ritlecitinib effectively promotes hair regrowth in severe and very severe alopecia areata.
research First drug for severe alopecia recommended by NICE could benefit 14,000 patients
Ritlecitinib can help about 14,000 people with severe hair loss.
research Marie Antoinette syndrome following COVID‐19 vaccination
A woman experienced sudden hair graying and loss after a COVID-19 vaccine, which improved with treatment.
research Pantolactams as androgen receptor antagonists for the topical suppression of sebum production
Pfizer found that pantolactam-based compounds can reduce sebum (skin oil) production when applied topically.
research Synthesis and biological evaluation of amino-pyridines as androgen receptor antagonists for stimulating hair growth and reducing sebum production
A compound made by Pfizer can potentially stimulate hair growth and reduce oil production, making it a good candidate for topical use.
research P063 Tracking down autoantibodies
A man developed autoimmune symptoms after the Pfizer COVID-19 vaccine, highlighting the need for thorough vaccine safety checks.
research Preparation of 4-aryl-2-trifluoromethylbenzonitrile derivatives as androgen receptor antagonists for topical suppression of sebum production
Scientists made a chemical (compound 4e) that can be applied on skin to reduce oil production, which can help with acne, but it might cause skin sensitivity to light.
research Diphenyl ethers as androgen receptor antagonists for the topical suppression of sebum production
Diphenyl ethers can potentially reduce excess oil production when applied on the skin, helping treat conditions like acne.
research Ritlecitinib: First Approval
Ritlecitinib is approved in the USA and Japan for treating severe hair loss in people aged 12 and older.
research Subpopulations of dermal skin fibroblasts secrete distinct extracellular matrix: implications for using skin substitutes in the clinic
Different skin cells produce unique materials, which can improve skin substitutes for healing.
research A case of severe autoimmune hemolytic anemia after a receipt of a first dose of SARS‐CoV‐2 vaccine
An 84-year-old man developed severe anemia after his first COVID-19 vaccine shot, improved with treatment, and was advised against a second dose.
research Bacillus Calmette-Guerin (BCG) Site Reaction After Coronavirus Disease 2019 (COVID-19) mRNA Vaccination
BCG site reactions after COVID-19 mRNA vaccination are mild, temporary, and likely under-reported.